Global Drug-Eluting Balloons Market Size By Type (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon), By Application (Hospitals and Ambulatory Surgery Centers, CATH Labs), By Region, And...

The Global Drug-Eluting Balloons (DEB) Market was valued at USD 721 million in 2023 and is projected to reach USD 1.43 billion by 2031, expanding at a CAGR of 8.9% from 2023 to 2031. The market is witnessing significant growth due to the rising prevalence of cardiovascular diseases, particularly peripheral artery disease (PAD) and coronary artery disease (CAD). Drug-eluting balloons are emerging as a preferred alternative to traditional stents, offering anti-restenotic drug delivery without leaving a permanent implant, thus reducing the risk of long-term complications.

The increasing geriatric population, advancements in balloon catheter technology, and growing demand for minimally invasive procedures are propelling market growth. Furthermore, favorable reimbursement policies in developed regions and ongoing clinical trials demonstrating efficacy are reinforcing the adoption of DEBs in both hospitals and ambulatory surgical centers.

Drivers:

1. Rising Prevalence of Cardiovascular Diseases:

Aging populations and sedentary lifestyles are contributing to the global surge in PAD and CAD, necessitating effective revascularization therapies such as DEBs.

2. Advantages Over Traditional Stents:

Unlike drug-eluting stents, DEBs eliminate the need for a permanent scaffold, reducing long-term complications like stent thrombosis and allowing for more flexible treatment strategies.

3. Technological Advancements:

Innovations in drug delivery coatings, catheter designs, and balloon material are enhancing procedural success rates and boosting physician confidence in using DEBs.

Restraints:

1. High Cost and Limited Reimbursement in Emerging Markets:

While reimbursement policies in North America and Europe are supportive, developing countries face financial and infrastructural constraints that limit DEB accessibility.

2. Lack of Long-Term Clinical Data:

Although short- and mid-term results are promising, the market still lacks extensive long-term outcome studies, which restrains rapid adoption in conservative medical settings.

Opportunity:

1. Expansion into Emerging Economies:

Markets in Asia-Pacific and Latin America represent untapped growth potential due to rising healthcare expenditures and expanding catheterization laboratory infrastructure.

2. Integration with Image-Guided and AI-Assisted Systems:

Future DEB technologies may integrate with advanced imaging systems and AI-based decision tools, creating differentiated offerings and improving procedural outcomes.

Market by System Type Insights:

In 2023, the Paclitaxel-Eluting Balloon segment accounted for the largest share due to its proven clinical efficacy in preventing restenosis. Paclitaxel’s lipophilic nature enables rapid uptake by the vessel wall, making it ideal for drug delivery via balloons. However, the Sirolimus-Eluting Balloon segment is anticipated to witness the highest growth during the forecast period owing to its superior safety profile and increasing FDA approvals.

Market by End-Use Insights:

The Hospital segment dominated the market in 2023, comprising over 60% of total revenue. Hospitals remain the primary sites for complex cardiovascular interventions due to advanced infrastructure and availability of skilled interventional cardiologists. The Ambulatory Surgical Centers (ASCs) segment is projected to grow rapidly, supported by the trend toward outpatient procedures, lower costs, and reduced hospital stays.

Market by Regional Insights:

North America led the global market in 2023, driven by high healthcare spending, favorable reimbursement, and widespread use of advanced cardiovascular technologies. Europe follows closely, benefiting from a robust network of cardiac care units and increasing awareness of DEB benefits. However, Asia-Pacific is expected to register the fastest growth during the forecast period due to improving healthcare access, increasing disease burden, and strong government initiatives to modernize cardiovascular care.

Competitive Scenario:

Prominent players in the Global Drug-Eluting Balloons Market include Medtronic plc, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cardionovum GmbH, Concept Medical Inc., and Cook Medical LLC. These companies are actively investing in R&D, clinical trials, and regulatory approvals to enhance their DEB product portfolios.

Key Developments:

In 2023, Medtronic received expanded FDA approval for its IN.PACT™ AV drug-coated balloon for use in arteriovenous fistula stenosis.

In 2024, BIOTRONIK launched a next-gen sirolimus-coated balloon featuring micro-reservoir technology for enhanced drug retention.

In 2025, Concept Medical gained CE mark approval for their MagicTouch™ sirolimus-coated balloon targeting coronary indications.

Scope of Work – Global Drug-Eluting Balloons Market

Report Metric Details

Market Size (2023) USD 721 million

Projected Market Size (2031) USD 1.43 billion

CAGR (2023-2031) 8.9%

Market Segments By System Type (Paclitaxel-Eluting, Sirolimus-Eluting), By End-Use (Hospitals, ASCs), By Region

Growth Drivers Rising cardiovascular cases, DEB advantages, tech innovation

Opportunities Expansion into emerging markets, AI-integrated systems

FAQs:

1) What is the current market size of the Global Drug-Eluting Balloons Market?

The market was valued at USD 721 million in 2023.

2) What is the major growth driver of the Global Drug-Eluting Balloons Market?

The primary growth driver is the rising prevalence of cardiovascular diseases and the preference for minimally invasive alternatives to stenting.

3) Which is the largest region during the forecast period in the Global Drug-Eluting Balloons Market?

North America holds the largest market share, with Asia-Pacific expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Drug-Eluting Balloons Market?

The Paclitaxel-Eluting Balloon segment dominated the market in 2023.

5) Who are the key market players in the Global Drug-Eluting Balloons Market?

Key players include Medtronic, Boston Scientific, BIOTRONIK, B. Braun, Concept Medical, and Cook Medical.